-
11.发明授权Vaginal tablets comprising misoprostol and methods of making and using the same 失效包含米索前列醇的阴道药片及其制备和使用方法公开(公告)号：US08148560B2
公开(公告)日：2012-04-03
申请号：US11526240
申请日：2006-09-25
申请人： Salah U. Ahmed , Raj R. Mahajan
发明人： Salah U. Ahmed , Raj R. Mahajan
IPC分类号： C07C59/147 , A61F6/12
CPC分类号： A61K9/0034 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K31/5575 , A61K31/57
摘要： The present invention is directed to vaginal tablets comprising misoprostol and a pharmaceutically acceptable pH insensitive, hydrophilic cellulose material, wherein the vaginal tablets do not contain a hydrophobic release controlling agent, and wherein the misoprostol and the pharmaceutically acceptable pH insensitive, hydrophilic cellulose material are in a ratio of about 1:50 to about 1:800, and wherein the vaginal tablets do not substantially change the pH of a vaginal tract.
摘要翻译： 本发明涉及包含米索前列醇和药学上可接受的pH不敏感的亲水性纤维素材料的阴道片剂，其中所述阴道片剂不含有疏水释放控制剂，并且其中所述米索前列醇和药学上可接受的pH不敏感的亲水性纤维素材料为 约1:50至约1:800的比例，并且其中所述阴道片基本上不改变阴道的pH。
-
公开(公告)号：US20110046115A1
公开(公告)日：2011-02-24
申请号：US12914478
申请日：2010-10-28
CPC分类号： A61K9/0056 , A61K9/2054 , C07D223/00
摘要： A non-effervescent, solid dosage form containing mirtazapine, which is used to form mirtazapine pharmaceutical tablets. The dosage form contains mirtazapine, a hydrophilic component, and at least one lubricant. In some embodiments, the dosage forms contain a salivating agent. Processes for producing mirtazapine orally disintegrating tablets are also provided.
摘要翻译： 含有米氮平的非泡腾固体剂型，用于形成米氮平药物片剂。 剂型含有米氮平，亲水组分和至少一种润滑剂。 在一些实施方案中，剂型含有唾液酸化剂。 还提供了生产米氮平口腔崩解片的方法。
-
公开(公告)号：US07838029B1
公开(公告)日：2010-11-23
申请号：US10902836
申请日：2004-08-02
IPC分类号： A61K9/20 , C07D223/00
CPC分类号： A61K9/0056 , A61K9/2054 , C07D223/00
摘要： A non-effervescent, solid dosage form containing mirtazapine, which is used to form mirtazapine pharmaceutical tablets. The dosage form contains mirtazapine, a hydrophilic component, and at least one lubricant. In some embodiments, the dosage forms contain a salivating agent. Processes for producing mirtazapine orally disintegrating tablets are also provided.
摘要翻译： 含有米氮平的非泡腾固体剂型，用于形成米氮平药物片剂。 剂型含有米氮平，亲水组分和至少一种润滑剂。 在一些实施方案中，剂型含有唾液酸化剂。 还提供了生产米氮平口腔崩解片的方法。
-
14.发明申请公开(公告)号：US20090196935A1
公开(公告)日：2009-08-06
申请号：US12364241
申请日：2009-02-02
IPC分类号： A61K9/14 , A61K31/519 , A61P25/00
CPC分类号： A61K9/5073 , A61K9/5078 , A61K31/519 , A61K31/616 , A61K2300/00
摘要： The present invention is directed to pharmaceutical capsules comprising extended release formulations of dipyridamole, processes for preparing such dipyridamole extended release formulations and their use in the treatment of stroke.
摘要翻译： 本发明涉及包含双嘧达莫的延长释放制剂的药物胶囊，制备这种双嘧达莫延长释放制剂的方法及其在治疗中风中的应用。
-
15.发明授权Oral dosage forms comprising progesterone and methods of making and using the same 失效包含孕酮的口服剂型及其制备和使用方法公开(公告)号：US08663681B2
公开(公告)日：2014-03-04
申请号：US11441447
申请日：2006-05-26
申请人： Salah U. Ahmed , Charles E. Diliberti , Chandra Vattikonda , Sudhir R. Gorukanti , Sanjeev K. Gupta
发明人： Salah U. Ahmed , Charles E. Diliberti , Chandra Vattikonda , Sudhir R. Gorukanti , Sanjeev K. Gupta
IPC分类号： A61K31/56
CPC分类号： A61K9/4858 , A61K9/1623 , A61K9/1635 , A61K9/1664 , A61K9/485 , A61K9/4866 , A61K31/57
摘要： The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.
摘要翻译： 本发明涉及包含微粉化孕酮，食用油，崩解剂和亲水赋形剂的口服药物剂型。 特别地，本发明涉及药物剂型，其中剂型为粉末形式并且包含在药学上可接受的胶囊中。 本发明还涉及制备剂型的方法，使用剂型的方法和包含该剂型的试剂盒。
-
公开(公告)号：US20110287096A1
公开(公告)日：2011-11-24
申请号：US13110591
申请日：2011-05-18
CPC分类号： A61K9/0065 , A61K9/0007 , A61K9/2081 , A61K9/5084 , A61K31/425 , A61K31/506 , A61K2300/00
摘要： Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of a mammal to which such dosage forms are administered. Such dosage forms include tablets and capsules. Such dosage forms provide improved bioavailability of otherwise poorly bioavailable basic amine drugs.
摘要翻译： 用于碱性胺药物的口服剂型，所述剂型具有胃保持成分和非保留性成分。 这些剂型能够提供这些药物的IR和SR释放速率。 此外，它们提供了在施用这种剂型的哺乳动物的胃和/或肠中释放药物。 这样的剂型包括片剂和胶囊剂。 这样的剂型提供了其他生物可利用的碱性胺药物的改善的生物利用度。
-
17.发明授权Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof 有权口服崩解包含孕激素的固体剂型及其制备和使用方法公开(公告)号：US07867515B2
公开(公告)日：2011-01-11
申请号：US12003234
申请日：2007-12-20
IPC分类号： A61K9/20
CPC分类号： A61K31/56 , A61K9/0056 , A61K9/2018 , A61K9/2054
摘要： The present invention is directed to non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising progestin and methods of making and using the dosage forms to treat conditions in females in need thereof.
摘要翻译： 本发明涉及包含孕激素的非泡腾口腔崩解固体药物剂型，以及制备和使用该剂型以治疗有需要的女性中的病症的方法。
-
18.发明申请Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof 有权口服崩解包含孕激素的固体剂型及其制备和使用方法公开(公告)号：US20080175906A1
公开(公告)日：2008-07-24
申请号：US12003234
申请日：2007-12-20
CPC分类号： A61K31/56 , A61K9/0056 , A61K9/2018 , A61K9/2054
摘要： The present invention is directed to non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising progestin and methods of making and using the dosage forms to treat conditions in females in need thereof.
摘要翻译： 本发明涉及包含孕激素的非泡腾口腔崩解固体药物剂型，以及制备和使用该剂型以治疗有需要的女性中的病症的方法。
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.032 秒)
